# Switching Study From Lamivudine to Clevudine in the Chronic Hepatitis B Patients

> **NCT00558493** · PHASE4 · COMPLETED · sponsor: **Bukwang Pharmaceutical** · enrollment: 100 (estimated)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** Clevudine

## Key facts

- **NCT ID:** NCT00558493
- **Lead sponsor:** Bukwang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2012-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00558493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00558493, "Switching Study From Lamivudine to Clevudine in the Chronic Hepatitis B Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00558493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*